» Articles » PMID: 20726512

Orally Active MMP-1 Sparing α-tetrahydropyranyl and α-piperidinyl Sulfone Matrix Metalloproteinase (MMP) Inhibitors with Efficacy in Cancer, Arthritis, and Cardiovascular Disease

Abstract

α-Sulfone-α-piperidine and α-tetrahydropyranyl hydroxamates were explored that are potent inhibitors of MMP's-2, -9, and -13 that spare MMP-1, with oral efficacy in inhibiting tumor growth in mice and left-ventricular hypertrophy in rats and in the bovine cartilage degradation ex vivo explant system. α-Piperidine 19v (SC-78080/SD-2590) was selected for development toward the initial indication of cancer, while α-piperidine and α-tetrahydropyranyl hydroxamates 19w (SC-77964) and 9i (SC-77774), respectively, were identified as backup compounds.

Citing Articles

The (Mānuka)-Specific Nectar and Honey Compound 3,6,7-Trimethyllumazine (Lepteridine) That Inhibits Matrix Metalloproteinase 9 (MMP-9) Activity.

Lin B, Nair S, Fellner D, Nasef N, Singh H, Negron L Foods. 2023; 12(22).

PMID: 38002130 PMC: 10670905. DOI: 10.3390/foods12224072.


Novel Matrix Metalloproteinase-9 (MMP-9) Inhibitors in Cancer Treatment.

Rashid Z, Bardaweel S Int J Mol Sci. 2023; 24(15).

PMID: 37569509 PMC: 10418771. DOI: 10.3390/ijms241512133.


Matrix Metalloproteinases Inhibitors in Cancer Treatment: An Updated Review (2013-2023).

Almutairi S, Kalloush H, Manoon N, Bardaweel S Molecules. 2023; 28(14).

PMID: 37513440 PMC: 10384300. DOI: 10.3390/molecules28145567.


Carborane-Containing Hydroxamate MMP Ligands for the Treatment of Tumors Using Boron Neutron Capture Therapy (BNCT): Efficacy without Tumor Cell Entry.

Flieger S, Takagaki M, Kondo N, Lutz Jr M, Gupta Y, Ueda H Int J Mol Sci. 2023; 24(8).

PMID: 37108137 PMC: 10139035. DOI: 10.3390/ijms24086973.


New Boron Delivery Agents.

Beck-Sickinger A, Becker D, Chepurna O, Das B, Flieger S, Hey-Hawkins E Cancer Biother Radiopharm. 2022; 38(3):160-172.

PMID: 36350709 PMC: 10325817. DOI: 10.1089/cbr.2022.0060.